Osteosarcoma – Combination of Electroporation of Metabolic Modulators with Low dose chemotherapy

Posted on: 15 Jun 2018

Osteosarcoma – Combination of Electroporation of Metabolic Modulators with Low dose chemotherapy

 

 

Principal Investigator: Dr. Patrick Forde

Lead Researcher: Dr. Kheshwant Gill

 

Bone cancer particularly osteosarcoma can be an aggressive disease. Despite tremendous advances in diagnostic modalities, surgical procedures, and chemotherapy options, osteosarcoma confers a generally poor prognosis. The absence of an effective immune response to most types of osteosarcoma is thought to contribute to the poor prognosis. Several studies have indicated improved prognosis with the presence of immune cell infiltration in many tumour types; including osteosarcoma. Harnessing or re-programming the body’s own immune system to treat osteosarcoma has the potential to be a very effective treatment strategy.

The project proposes to merge tumour ECT cell death response, cellular stress inducers and anti-tumour immunity within a clinically significant single paradigm. This regime has the potential to elicit their full combined therapeutic benefit. Secondly, the project intends to build upon the local ECT by identifying DAMP inducing immunogenic chemotherapies that can synergise with stress inducer, allowing for generation of an abscopal effect. Thirdly, the project identifies the optimum sequence for the treatment.

We believe the proposed treatment strategy has many advantages including reduced chemotherapy (100-fold less) required by electroporation and the cytotoxicity of the stress inducer will be localized to tumour by targeted electroporation delivery. Therefore, the proposed treatment has the potential to be a safe, minimally invasive therapy with fewer side effects than the current best standard of care for metastatic osteosarcoma.

© Site Designed by Granite Digital